GIP/GLP-1/Glucagon Triple Receptor Agonist
Retatrutide
Triple GIP, GLP-1, and glucagon receptor agonist studied for advanced metabolic regulation and weight reduction in research settings.
Select Size
Tested by: Eurofins Scientific · Batch: VRC-RET-2406 · Jun 2026
About Retatrutide
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor agonism to the dual GIP/GLP-1 mechanism is hypothesized to further enhance energy expenditure and hepatic fat reduction. Early clinical research has shown substantial weight loss and metabolic improvements, making it a significant research tool in obesity and metabolic disease models.
Research Areas
Technical Specifications
Molecular Weight
4973.61 g/mol
Amino Acid Sequence
Triple receptor agonist peptide — proprietary sequence analog
Storage
Lyophilized: −20°C, stable 24 months. Reconstituted: 4°C, use within 28 days.
Solubility
Soluble in 10mM PBS pH 7.4 at ≥1 mg/mL
For Research Purposes Only. Retatrutide is sold exclusively for in vitro laboratory research. Not for human consumption, diagnostic, therapeutic, or veterinary use. See our Research Use Disclaimer.